Altimmune Inc (NAS:ALT)
$ 7.33 -0.06 (-0.81%) Market Cap: 519.71 Mil Enterprise Value: 342.50 Mil PE Ratio: 0 PB Ratio: 3.00 GF Score: 30/100

Altimmune Inc Acceptance of IND for Covid-19 Therapeutic Testing - Call Transcript

Jun 01, 2020 / 12:30PM GMT
Release Date Price: $8.64 (-6.90%)
Operator

Greetings. Welcome to Altimmune, Inc. T-COVID Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

It is now my pleasure to introduce your host, Ms. Monique Kosse with LifeSci Advisors. Thank you. You may begin.

Monique Kosse
LifeSci Advisors, LLC - MD

Thank you, operator, and thank you, everyone, for participating in today's T-COVID Conference Call. Leading the call today will be Vipin Garg, Chief Executive Officer of Altimmune. Also participating on the call today is Scot Roberts, Chief Scientific Officer; Scott Harris, Chief Medical Officer; and Will Brown, Chief Financial Officer.

After their prepared remarks, we will open up the call for a question-and-answer session. A press release announcing the launch of the T-COVID program was issued this morning and can be found on the Investors page of the company's website.

Before we begin, I would like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for the purposes of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot